Su Ying

[1] 刘鸷驹, 张东星, 晏仁义, 等. γ-氨基丁酸的生物活性研究进展[J]. 现代药物与临床,2022,37(9):2167−2172. [LIU Zhiju, ZHANG Dongxing, YAN Renyi, et al. Research progress on biological activities of γ-aminobutyric acid[J]. Drugs & Clinic,2022,37(9):2167−2172. LIU Zhiju, ZHANG Dongxing, YAN Renyi, et al. Research progress on biological activities of γ-aminobutyric acid[J]. Drugs & Clinic, 2022, 37(9): 2167-2172. [2] 李海峰, 李冰冰, 石硕硕, 等. γ-氨基丁酸在食品中的应用研究进展[J]. 河南工业大学学报(自然科学版),2023,44(1):117−125. [LI Haifeng, LI Bingbing, SHI Shuoshuo, et al.

Drug Safety, Aug 2023 Trastuzumab deruxtecan (T-DXd)—an antibody–drug conjugate targeting the human epidermal growth factor receptor 2 (HER2)—improved outcomes of patients with HER2-positive and HER2-low metastatic breast cancer. Guidance on monitoring and managing T-DXd–related adverse events (AEs) is an emerging unmet need as translating clinical trial experience into real-world practice may be difficult due to practical and cultural considerations and differences in health care infrastructure.